ribociclib + Trametinib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumors for Phase Ib
Conditions
Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II
Trial Timeline
Jun 29, 2016 → Sep 24, 2019
NCT ID
NCT02703571About ribociclib + Trametinib
ribociclib + Trametinib is a phase 1 stage product being developed by Novartis for Solid Tumors for Phase Ib. The current trial status is terminated. This product is registered under clinical trial identifier NCT02703571. Target conditions include Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02703571 | Phase 1 | Terminated |
Competing Products
20 competing products in Solid Tumors for Phase Ib